Skip to main content
BIDE PHARMATECH CO., LTD. logo

BIDE PHARMATECH CO., LTD. — Investor Relations & Filings

Ticker · 688073 ISIN · CNE100005NV3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 484 across all filing types
Latest filing 2026-05-18 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688073

About BIDE PHARMATECH CO., LTD.

https://www.bidepharmatech.com/

Bide Pharmatech Co., Ltd. specializes in the research, development, and supply of high-quality chemical building blocks and specialty reagents for the global pharmaceutical and biotechnology sectors. The company offers an extensive portfolio of small molecule organic compounds, including functionalized heterocycles, catalysts, ligands, and advanced intermediates essential for drug discovery and chemical research. Bide Pharmatech provides comprehensive services ranging from catalog product distribution to custom synthesis and contract research, supporting clients through various stages of the drug development lifecycle. With a focus on technical innovation and rigorous quality control, the firm facilitates efficient lead optimization and process development for academic institutions and commercial laboratories worldwide.

Recent filings

Filing Released Lang Actions
股东减持股份计划公告
Major Shareholding Notification Classification · 85% confidence The document is a “股东减持股份计划公告” by existing shareholders detailing their plan to sell down equity holdings over a specific period. It is not a company financial report, earnings release, board change, or dividend notice. It is a regulatory announcement regarding changes in major shareholdings (a planned reduction by significant shareholders). Thus it fits the “Major Shareholding Notification” category (MRQ).
2026-05-18 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the formal 2025 Annual General Meeting resolution announcement of Shanghai Bide Medical Technology Co., Ltd., detailing attendance, agenda items, and individual vote tallies (agree/oppose/abstain) for each proposal. This is precisely an official declaration of shareholder meeting voting results rather than the meeting materials themselves or a full annual report. Therefore, it matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-05-13 Chinese
国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings
2026-05-08 Chinese
国泰海通证券股份有限公司关于上海毕得医药科技股份有限公司2025年度持续督导年度跟踪报告
Regulatory Filings
2026-05-08 Chinese
董事会审计委员会关于会计师事务所2025年度履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Board Audit Committee regarding the performance and supervision of the external audit firm (Zhonghui CPA Firm) for the fiscal year 2025. It discusses the audit firm's qualifications, independence, audit procedures, communication with management, and the audit committee's oversight activities related to the 2025 annual audit. The document references the 2025 annual report audit work and the issuance of the audit opinion but does not contain the actual financial statements or the audit report itself. It is a supervisory report on the audit firm's performance rather than the audit report or the annual report itself. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and information about audit procedures and results of internal or regulatory oversight related to audits, excluding the full annual report. The document length is 2531 characters, which is relatively short but contains substantive information about audit oversight, not just an announcement or certification. Therefore, the appropriate classification is AR with high confidence.
2026-04-22 Chinese
内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制审计报告" which translates to "Internal Control Audit Report." It is issued by a certified accounting firm and addresses the effectiveness of internal control over financial reporting for the fiscal year ending December 31, 2025. The content includes auditor responsibilities, management responsibilities, and an audit opinion on internal control effectiveness. There is no indication that this is a full annual report or interim report, but rather a standalone audit report focused on internal control. The document length is 3084 characters, which is consistent with a standalone audit report rather than a brief announcement or certification letter. Therefore, this document fits the category of Audit Report / Information (AR).
2026-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.